glycopyrronium


Also found in: Wikipedia.

glycopyrrolate, glycopyrronium

an anticholinergic used to reduce gastric acid secretion and hypermotility.
References in periodicals archive ?
Glycopyrrolate (also known as glycopyrronium bromide) was exclusively licensed to Novartis in April 2005 by Vectura and its co-development partner Sosei.
PSX1002, a drug-only proprietary formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), currently in Phase 2 clinical studies for COPD in pMDI, and
such as glycopyrronium bromide in the treatment of airway disease will
The company will be launching clinical trials for a new cardiology medication for premature newborn infants, and glycopyrronium a drug designed to combat sialorrhoea, or chronic pathological drooling in the first quarter.
These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide), both of which are currently in Phase III development.
12) Anticholinergic drugs such as glycopyrronium bromide and Robinul (First Horizon Pharmaceutical Corp .
Five studies in the program - comprising 10 studies in total with more than 7,000 patients across 42 countries - all met their primary endpoints and showed that QVA149 significantly improved lung function compared to other COPD therapies like tiotropium, indacaterol, salmeterol/fluticasone and glycopyrronium bromide.
Among key abstracts being presented at ERS are the positive Phase III safety and efficacy data for PT003, the investigational therapy combining glycopyrronium and formoterol fumarate in a pressurised metered dose inhaler (pMDI).
Abell E, Morgan K: The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis.
The FLIGHT 1 and 2 studies met their primary objectives with twice-daily QVA149 demonstrating statistically significant and clinically meaningful improvements in lung function (FEV1 AUC0-12) at Week 12, compared to indacaterol and glycopyrronium bromide in moderate-to-severe COPD patients.
First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix ' novel particle-engineering technology